SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP
level are in the top quintile will be offered participation in this study. Participants will
be randomised to receive either spironolactone or placebo for three years. Participants will
then be monitored for indications of heart failure. It is anticipated that the medication
will reduce the development of heart failure in this group.